WCLC 2025 - Posters & ePosters-EP.12.44 The Efficacy of Capmatinib in Treating NSCLC Patients With MET Amplification in a Multi-Center Real-World Setting

EP.12.44 The Efficacy of Capmatinib in Treating NSCLC Patients With MET Amplification in a Multi-Center Real-World Setting

Back to course

Pdf Summary

This multi-center retrospective study evaluated the efficacy and safety of capmatinib, a selective MET tyrosine kinase inhibitor, in treating Chinese patients with non-small cell lung cancer (NSCLC) harboring MET amplification, either as a de novo driver alteration or acquired resistance (AR) following prior tyrosine kinase inhibitor (TKI) therapy. MET amplification occurs in approximately 1%-5% of untreated NSCLC and plays a significant oncogenic role.<br /><br />A total of 24 patients (median age 55) from six centers were included, with 23 adenocarcinoma cases and one squamous carcinoma. Of these, 3 had de novo MET amplification, 18 acquired after TKI treatment, and 3 had unknown MET status. One-third had brain metastases at diagnosis. Patients received a median of 3 lines of capmatinib-based treatment.<br /><br />The median real-world progression-free survival (rwPFS) was 7.1 months overall and 10.1 months among the 19 patients with known MET gene copy number (GCN). Median overall survival (OS) was 40 months in the whole cohort, with 14.6 months for patients with documented de novo or acquired amplification. The objective response rate (ORR) was 33.3% across all patients and 42.1% in those with known MET alterations; disease control rates (DCR) exceeded 89%. Stratification by various GCN cutoffs (5, 6.55, 10) showed no statistically significant differences in PFS or OS, though numerically higher GCN (≥10) tended toward better PFS.<br /><br />Safety data from 19 patients revealed manageable adverse events, predominantly peripheral edema (36.8%) and hypoalbuminemia (15.8%). Only two patients experienced grade 3 or higher events, including one case of interstitial pneumonia which resolved with treatment; no treatment-related deaths occurred.<br /><br />This is the first real-world Chinese study supporting capmatinib as a promising monotherapy or combination option for NSCLC patients with MET amplification. MET GCN may serve as a potential biomarker for response prediction. The manageable safety profile further supports capmatinib’s clinical utility in this population.

Asset Subtitle

Ning Yan

Meta Tag

Speaker Ning Yan

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

capmatinib

MET amplification

non-small cell lung cancer

NSCLC

tyrosine kinase inhibitor

real-world study

progression-free survival

overall survival

objective response rate

adverse events